CDMO

#CDMO #Manufacturing

Ten23 announces Swiss manufacturing expansion  

Global contract development and manufacturing organisation (CDMO) ten23 health has announced an expansion to its facility in Switzerland.  The company is expanding swissfillon’s manufacturing site, a sterile filling supplier who joined ten23 in 2021.   Ten23 will expand the site with a new manufacturing… Read More

#News

#CDMO #Manufacturing

Bachem & Eli Lilly partner on oligonucleotide project  

Swiss pharmaceutical company Bachem has partnered with Eli Lilly on a seven-year agreement to advance the development of oligonucleotide-based drug substances.   The agreement will see the two companies contribute to global manufacturing capacity for oligonucleotide-based medicines for patients.  Through the collaboration Bachem will… Read More

#News

#Biomanufacturing #CDMO

Matica Biotechnology expands viral vector capacity  

Contract development and manufacturing organisation (CMDO) Matica Biotechnology has opened a new facility for the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.  Through the facility, Matica Bio is expanding its capacity as a CDMO… Read More

#News

#API #CDMO

Onyx Scientific expands API offering 

Contract development and manufacturing organisation (CDMO) Onyx Scientific has opened a second facility in North East England, expanding its offerings.   The company’s new site doubles Onyx Scientific’s current footprint and will enable it to expand all Chemistry, Manufacturing and Controls (CMC) activities. The facility will also enable… Read More

#News

#CDMO #Drug development

Quotient Sciences acquires Arcinova, a UK CDMO

Quotient Sciences, the drug development and manufacturing accelerator, has acquired Arcinova, the UK-based multiservice contract development and manufacturing organisation (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide. The acquisition expands Quotient’s… Read More

#News

#AMR #CDMO #Covid-19 #Immunology / Virology & Vaccines #RNA

Vaccine nationalism, AMR & CDMO expansion ahead for 2021

The new CPhI report looks ahead to a post-pandemic 2021 with pharma manufacturing capacity and payment structures shifting as new sourcing strategies emerge. It explores the potential implications in 2021 of impending vaccine approvals, a new administration in the White House and a return to dual supply chain strategies. The report… Read More

#Business & Investment #Covid-19 #Editor's Choice #Market Reports #News